Wow!
“The existing (heart failure) therapies are essentially diuretics reducing total circulating volume (SGLT2 inhibitors and Entresto). This reduction in preload prevents backflow into the lungs from a dilated non compliant left ventricle, and reduces symptomatic shortness of breath. MSB’s Rexlemestrocel doesn’t have any effect on preload, but it reduces left ventricular inflammation, improves micro vascular flow and protects viable cardiomyocytes against death. That increases contractility and forward flow, resulting in reduction of heart attacks, strokes and death.” - Dr. Itescu on the mechanism of action
”With the goal of getting a new cell therapy approved for heart failure, the primary endpoint was to prove that the therapy could prevent recurrent hospitalizations.“It was a total negative,” says Perin. That’s because the cells don’t have a decongestant effect such as the medicines currently used to treat heart failure.But that doesn’t mean that the trial was a failure. Quite the opposite. That’s because Perin
and his team proved something else: The trial was able to prove that there was significant improvement in patients with inflammation. After those patients were injected with mesenchymal precursor cells (MPC), they showed a 70-percent reduction in heart attacks and strokes. Cardiovascular deaths also decreased.” - Dr. Perin (extract from above link)
- Forums
- ASX - By Stock
- MSB
- Cell Therapy News/Articles
Cell Therapy News/Articles, page-17138
-
-
- There are more pages in this discussion • 683 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
(20min delay)
|
|||||
Last
$1.19 |
Change
0.085(7.69%) |
Mkt cap ! $1.358B |
Open | High | Low | Value | Volume |
$1.10 | $1.20 | $1.09 | $13.21M | 11.37M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | $1.19 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.19 | 75212 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 15000 | 1.185 |
1 | 20000 | 1.175 |
1 | 5664 | 1.170 |
1 | 17568 | 1.160 |
3 | 56695 | 1.150 |
Price($) | Vol. | No. |
---|---|---|
1.190 | 59712 | 2 |
1.195 | 36255 | 5 |
1.200 | 404381 | 31 |
1.205 | 3000 | 1 |
1.210 | 162475 | 7 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
FWD
Queensland's housing crisis an opportunity for ASX builder Fleetwood – and taxpayer cash a safe harbour from the storm
SKS
SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne
MSB (ASX) Chart |